An International Expanded Access Clinical Programme With ZD1839 (IRESSA) [gefitinib] for Patients With Advanced Non-Small Cell Lung Cancer(NSCLC) and Patients With Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck (H and NC).

Trial Profile

An International Expanded Access Clinical Programme With ZD1839 (IRESSA) [gefitinib] for Patients With Advanced Non-Small Cell Lung Cancer(NSCLC) and Patients With Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck (H and NC).

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Expanded access
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 10 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top